Advances in the medical treatment of diabetic retinopathy.
Simó
Rafael
R
CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud CarlosIII, Madrid, Spain. rsimo@ir.vhebron.net
Hernández
Cristina
C
D001766:Blindness / Q000453:epidemiology / Q000517:prevention & control*; D001813:Blood-Retinal Barrier / Q000502:physiology / Q000503:physiopathology; D008076:Cholesterol, HDL / Q000097:blood / Q000187:drug effects; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000453:epidemiology / Q000503:physiopathology*; D003930:Diabetic Retinopathy / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D050171:Dyslipidemias / Q000188:drug therapy; D011345:Fenofibrate / Q000627:therapeutic use; D006801:Humans; D015228:Hypertriglyceridemia / Q000188:drug therapy; D008269:Macular Edema / Q000150:complications; D015995:Prevalence; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology; D014280:Triglycerides / Q000097:blood; D014792:Visual Acuity
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D014280:Triglycerides; D011345:Fenofibrate